Weiwei Lai
Impact in
- Cancer Research top 1%
- Cancer-related molecular mechanisms research
- Cancer, Lipids, and Metabolism
- MicroRNA in disease regulation
-
- Ferroptosis and cancer prognosis
Papers in
-
- RNA modifications and cancer 12
- Epigenetics and DNA Methylation 6
- RNA Research and Splicing 2
- Circular RNAs in diseases 2
-
- Cancer-related molecular mechanisms research 10
- Cancer, Hypoxia, and Metabolism 2
- Co-authors
- Yongguang Tao (18 shared papers)Ya Cao (14 shared papers)Desheng Xiao (14 shared papers)Chao Mao (10 shared papers)Yating Liu (9 shared papers)Hu Zhou (6 shared papers)Min Wang (5 shared papers)Shuang Liu (5 shared papers)
- Journals
- Theranostics (2 papers)Cell Death and Differentiation (2 papers)Oncotarget (2 papers)Signal Transduction and Targeted Therapy (2 papers)Molecular Pharmaceutics (1 paper)
- Partner nations
- ChinaSaudi ArabiaUnited States
In The Last Decade
Weiwei Lai
26 papers receiving 1.6k citations
Weiwei Lai's Hit Papers
Peers
Comparison fields: 5 of 88
- Cancer Research 1.1k
- Pulmonary and Respiratory Medicine 822
- Molecular Biology 1.2k
- Oncology 121
- Immunology 63
Countries citing papers authored by Weiwei Lai
This map shows the geographic impact of Weiwei Lai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiwei Lai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiwei Lai more than expected).
Fields of papers citing papers by Weiwei Lai
This network shows the impact of papers produced by Weiwei Lai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiwei Lai. The network helps show where Weiwei Lai may publish in the future.
Co-authors
The 25 scholars most cited alongside Weiwei Lai, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 28 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Long noncoding RNA LINC00336 inhibits ferroptosis in lung cancer by functioning as a competing endogenous RNA Hit paper breakdown → | 2019 | 429 |
| 2 | A G3BP1-Interacting lncRNA Promotes Ferroptosis and Apoptosis in Cancer via Nuclear Sequestration of p53 Hit paper breakdown → | 2018 | 402 |
| 3 | 2017 | 233 | |
| 4 | 2022 | 53 | |
| 5 | 2022 | 47 | |
| 6 | 2017 | 44 | |
| 7 | 2019 | 41 | |
| 8 | 2018 | 37 | |
| 9 | 2014 | 33 | |
| 10 | 2017 | 33 | |
| 11 | 2023 | 29 | |
| 12 | 2019 | 26 | |
| 13 | 2023 | 24 | |
| 14 | 2020 | 24 | |
| 15 | 2016 | 23 | |
| 16 | 2019 | 22 | |
| 17 | 2020 | 13 | |
| 18 | 2024 | 13 | |
| 19 | 2013 | 11 | |
| 20 | 2024 | 9 |
About Weiwei Lai
Weiwei Lai is a scholar working on Molecular Biology, Cancer Research, Pulmonary and Respiratory Medicine, Immunology and Cardiology and Cardiovascular Medicine, having authored 28 papers that have together received 1.6k indexed citations. Recurring topics across this work include RNA modifications and cancer (12 papers), Cancer-related molecular mechanisms research (10 papers), Epigenetics and DNA Methylation (6 papers), Ferroptosis and cancer prognosis (5 papers), RNA Research and Splicing (2 papers), Circular RNAs in diseases (2 papers), Cardiovascular Function and Risk Factors (2 papers) and Cancer, Hypoxia, and Metabolism (2 papers). The work is most often cited by research in Cancer Research (1.1k citations), Pulmonary and Respiratory Medicine (822 citations), Molecular Biology (1.2k citations), Oncology (121 citations) and Immunology (63 citations). Weiwei Lai has collaborated with scholars based in China, Saudi Arabia and United States. Frequent co-authors include Yongguang Tao, Ya Cao, Desheng Xiao, Chao Mao, Yating Liu, Hu Zhou, Min Wang, Shuang Liu, Bin Yan and Yiqun Jiang. Their work appears in journals such as Theranostics, Cell Death and Differentiation, Oncotarget, Signal Transduction and Targeted Therapy and Molecular Pharmaceutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.